DOP2006000153A - Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes - Google Patents

Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes

Info

Publication number
DOP2006000153A
DOP2006000153A DO2006000153A DO2006000153A DOP2006000153A DO P2006000153 A DOP2006000153 A DO P2006000153A DO 2006000153 A DO2006000153 A DO 2006000153A DO 2006000153 A DO2006000153 A DO 2006000153A DO P2006000153 A DOP2006000153 A DO P2006000153A
Authority
DO
Dominican Republic
Prior art keywords
compositions
iron oxide
oxide particles
magnetic iron
containing magnetic
Prior art date
Application number
DO2006000153A
Other languages
English (en)
Inventor
Andreas Briel
Bernhard Gleich
Jurgen Weizenecker
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of DOP2006000153A publication Critical patent/DOP2006000153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/418—Evaluating particular organs or parts of the immune or lymphatic systems lymph vessels, ducts or nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/0515—Magnetic particle imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Iron (AREA)
  • Soft Magnetic Materials (AREA)

Abstract

La presente invencion se refiere a complejos que contienen particulas magneticas de oxido de hierro en una cobertura aceptable para use farmaceutico, donde dichas particulas tienen un diametro entre 20nm y lµm con una proporcion entre el diametro total de particula y el diametro del nucleo menor de 6 y al use de dichos complejos en el diagnostico por imagenes con particulas magneticas (MPI). Se prefiere en particular el use de dichas composiciones en los examenes del tracto gastrointestinal, del sistema vascular cardiaco y componentes craneanos, en el diagnostico de arteriosclerosis, infartos, y tumores y metastasis, por ejemplo del sistema linfatico.
DO2006000153A 2005-06-29 2006-06-29 Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes DOP2006000153A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05014059A EP1738774A1 (de) 2005-06-29 2005-06-29 Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren

Publications (1)

Publication Number Publication Date
DOP2006000153A true DOP2006000153A (es) 2007-09-15

Family

ID=35432718

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000153A DOP2006000153A (es) 2005-06-29 2006-06-29 Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes

Country Status (12)

Country Link
EP (2) EP1738774A1 (es)
JP (1) JP5366542B2 (es)
CN (1) CN101378785B (es)
AR (1) AR054506A1 (es)
BR (1) BRPI0611755A2 (es)
DO (1) DOP2006000153A (es)
PA (1) PA8684301A1 (es)
PE (1) PE20070204A1 (es)
RU (1) RU2417104C2 (es)
TW (1) TW200711664A (es)
UY (1) UY29644A1 (es)
WO (1) WO2007000350A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1738773A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren
JP5353004B2 (ja) * 2007-01-05 2013-11-27 国立大学法人東京工業大学 球形フェライトナノ粒子の製造方法
JP5100212B2 (ja) 2007-06-15 2012-12-19 株式会社東芝 磁性微粒子イメージング装置、検出コイル配設方法および磁束検出装置
EP2274024B1 (en) * 2008-04-03 2013-05-15 Koninklijke Philips Electronics N.V. Biocompatible products for magnetic particle imaging
EP2406650A1 (en) 2009-03-09 2012-01-18 Koninklijke Philips Electronics N.V. Arrangement and method for measuring a magnetic material in a region of action
WO2010128418A1 (en) 2009-05-08 2010-11-11 Koninklijke Philips Electronics N.V. Arrangement and method for heating of a magnetic material
CN102686518B (zh) * 2009-11-20 2015-07-29 户田工业株式会社 磁性氧化铁微粒粉末、含有磁性颗粒的水分散体及其制造方法
WO2012007871A1 (en) 2010-07-13 2012-01-19 Koninklijke Philips Electronics N.V. System and method for generating a system function for use in the reconstruction of images
CN102092795B (zh) * 2010-12-11 2015-11-18 上海纳米技术及应用国家工程研究中心有限公司 有机高分子修饰的四氧化三铁多级球的制备方法
CA2778561C (en) * 2011-05-31 2020-10-13 Ghandi, Khashayar Magnetic nanocomposite material and processes for the production thereof
EP2647389A1 (en) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
US20150374855A1 (en) 2013-02-20 2015-12-31 Topass Gmbh Oral contrast medium for the diagnostic investigation of the gastrointestinal tract by means of mpi
CZ2014451A3 (cs) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
RU2582870C2 (ru) * 2014-07-16 2016-04-27 Акционерное общество "Государственный Ордена Трудового Красного Знамени научно-исследовательский институт химии и технологии элементоорганических соединений" (АО "ГНИИХТЭОС") Способ получения ферромагнитных металлических наночастиц с твердой изоляционной оболочкой
DE102014019388A1 (de) * 2014-12-29 2016-06-30 Susanne Wagner Arzneimittel auf der Basis von Maghämit zur gleichzeitigen Reduzierung der gastrointestinalen Natriumresorption und Phosphatresorption
JP2019151552A (ja) * 2016-07-12 2019-09-12 名糖産業株式会社 磁性粒子
DE102017108737A1 (de) 2017-04-24 2018-10-25 Universität Zu Lübeck Verfahren und Vorrichtung zur Herstellung von magnetischen Nanopartikeln
CN112970076A (zh) 2018-07-19 2021-06-15 贝克曼库尔特有限公司 磁性颗粒
CN111979794B (zh) * 2020-07-31 2022-01-04 盐城工学院 一种提高织物天然染料碱性浴染色效果的功能改性方法
CN112133553B (zh) * 2020-10-30 2021-12-21 福州大学 一种水基磁流体的连续制备方法
CN114028423B (zh) * 2021-12-13 2023-05-23 广东粤港澳大湾区国家纳米科技创新研究院 修饰的纳米氧化铁在制备预防和/或治疗炎性肠病的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689430B1 (de) * 1993-03-17 1997-08-13 Silica Gel Ges.M.B.H Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
EP0915738B1 (de) * 1996-08-05 2002-01-16 Schering Aktiengesellschaft Vorrichtung und verfahren zur abtrennung magnetischer materialien aus pharmazeutischen zubereitungen, deren ausgangs- oder zwischenprodukten sowie mit hilfe dieser vorrichtung hergestellte mittel
DE10151778A1 (de) * 2001-10-19 2003-05-08 Philips Corp Intellectual Pty Verfahren zur Ermittlung der räumlichen Verteilung magnetischer Partikel
JP4647590B2 (ja) * 2003-04-15 2011-03-09 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 物理的、化学的及び／又は生物学的な特性又は状態変数の空間的に解像される決定の方法
JP4890242B2 (ja) * 2003-04-15 2012-03-07 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 検査エリアにおける状態変数の空間分解を決定する装置及び方法
US20070258888A1 (en) * 2003-11-17 2007-11-08 Claus Feldmann Contrast Agent for Medical Imaging Techniques and Usage Thereof
EP1738773A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren

Also Published As

Publication number Publication date
CN101378785A (zh) 2009-03-04
TW200711664A (en) 2007-04-01
AR054506A1 (es) 2007-06-27
EP1738774A1 (de) 2007-01-03
PE20070204A1 (es) 2007-03-02
RU2008103202A (ru) 2009-08-10
JP5366542B2 (ja) 2013-12-11
BRPI0611755A2 (pt) 2012-04-17
WO2007000350A1 (en) 2007-01-04
EP1898959A1 (en) 2008-03-19
PA8684301A1 (es) 2007-01-17
UY29644A1 (es) 2007-01-31
JP2008546630A (ja) 2008-12-25
CN101378785B (zh) 2013-01-23
RU2417104C2 (ru) 2011-04-27

Similar Documents

Publication Publication Date Title
DOP2006000153A (es) Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes
DOP2006000154A (es) Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes
Mukherjee et al. The yin and yang of imaging tumor associated macrophages with PET and MRI
Qiao et al. Ultrasensitive in vivo detection of primary gastric tumor and lymphatic metastasis using upconversion nanoparticles
Ory et al. PET radioligands for in vivo visualization of neuroinflammation
Shevtsov et al. Granzyme B Functionalized Nanoparticles Targeting Membrane Hsp70‐Positive Tumors for Multimodal Cancer Theranostics
Georgiadou et al. Octadecylamine-mediated versatile coating of CoFe2O4 NPs for the sustained release of anti-inflammatory drug naproxen and in vivo target selectivity
SG149895A1 (en) Contrast agents for myocardial perfusion imaging
US20230330275A1 (en) Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto
Tu et al. Multimodality PET/MRI agents targeted to activated macrophages
Cormode et al. Nanoparticle contrast agents for CT: their potential and the challenges that lie ahead
JP2011519367A5 (es)
Ferreira et al. Current paradigm and future directions for treatment of Helicobacter pylori infection
Shen et al. Double‐balloon enteroscopy in the evaluation of small bowel disorders in pediatric patients
Deblock et al. Dual-Modality Hafnium Oxide Nanocrystals for in Vivo Computed Tomography and Fluorescence Imaging of Sentinel Lymph Nodes
US20200164081A1 (en) INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS
Siddiqui et al. An Engineered Probiotic Platform for Cancer Epitope‐Independent Targeted Radionuclide Therapy of Solid Tumors
ES2541787A1 (es) Compuestos y composiciones que comprenden nanotubos de carbono y compuestos de formula (I) y su uso como agentes de contraste
WO2018051289A3 (en) Novel liposomal gadolinium (gd) contrast agent "nmrx" for t1-mri
Khayat et al. Fibromatose mammaire: corrélations anatomo-radio-cliniques et revue de la littérature
Mirpour et al. Clinical stem cell imaging and in vivo tracking
Pal Current status of Helicobacter pylori associated human gastric cancer and the therapeutic approaches–A Review
Siddiqui Leveraging bacterial copper transporter for novel molecular imaging and therapeutic applications
CN104138604A (zh) 一种用CdTe和纳米铁合成磁共振成像造影剂的方法
Beiraghi Synthesis and Evaluation of Radiopharmaceuticals for Imaging Bacterial Infection